MA31206B1 - Dérivés cyclohexyl amide d'acide carboxylique aryle - Google Patents

Dérivés cyclohexyl amide d'acide carboxylique aryle

Info

Publication number
MA31206B1
MA31206B1 MA32193A MA32193A MA31206B1 MA 31206 B1 MA31206 B1 MA 31206B1 MA 32193 A MA32193 A MA 32193A MA 32193 A MA32193 A MA 32193A MA 31206 B1 MA31206 B1 MA 31206B1
Authority
MA
Morocco
Prior art keywords
derivatives
carboxylic acid
aryl carboxylic
cyclohexyl amide
amide aryl
Prior art date
Application number
MA32193A
Other languages
Arabic (ar)
English (en)
Inventor
René Hersperger
Philipp Janser
Wolfgang Miltz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31206B1 publication Critical patent/MA31206B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un composé représenté par la formule (i) ou un sel ou un promédicament de type ester pharmaceutiquement acceptables de celui-ci, les variants r et x de ladite formule étant tels que définis dans les spécifications.
MA32193A 2007-02-19 2009-08-31 Dérivés cyclohexyl amide d'acide carboxylique aryle MA31206B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07102622 2007-02-19
PCT/EP2008/051951 WO2008101905A1 (fr) 2007-02-19 2008-02-18 Dérivés cyclohexyl amide d'acide carboxylique aryle

Publications (1)

Publication Number Publication Date
MA31206B1 true MA31206B1 (fr) 2010-02-01

Family

ID=38058317

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32193A MA31206B1 (fr) 2007-02-19 2009-08-31 Dérivés cyclohexyl amide d'acide carboxylique aryle

Country Status (35)

Country Link
US (1) US8354431B2 (fr)
EP (1) EP2125782B1 (fr)
JP (1) JP5180234B2 (fr)
KR (1) KR101070984B1 (fr)
CN (1) CN101605781B (fr)
AR (1) AR065369A1 (fr)
AT (1) ATE518854T1 (fr)
AU (1) AU2008219317B2 (fr)
BR (1) BRPI0807625A2 (fr)
CA (1) CA2677565C (fr)
CL (1) CL2008000497A1 (fr)
CR (1) CR10957A (fr)
CY (1) CY1111984T1 (fr)
DK (1) DK2125782T3 (fr)
EA (1) EA017000B1 (fr)
EC (1) ECSP099584A (fr)
ES (1) ES2371126T3 (fr)
GT (1) GT200900226A (fr)
HN (1) HN2009001607A (fr)
HR (1) HRP20110793T1 (fr)
IL (1) IL200191A (fr)
MA (1) MA31206B1 (fr)
MX (1) MX2009008145A (fr)
MY (1) MY147487A (fr)
NZ (1) NZ578663A (fr)
PE (1) PE20081785A1 (fr)
PL (1) PL2125782T3 (fr)
PT (1) PT2125782E (fr)
RS (1) RS51986B (fr)
SI (1) SI2125782T1 (fr)
TN (1) TN2009000345A1 (fr)
TW (1) TW200848038A (fr)
UA (1) UA97389C2 (fr)
WO (1) WO2008101905A1 (fr)
ZA (1) ZA200905160B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
US11591544B2 (en) 2020-11-25 2023-02-28 Akagera Medicines, Inc. Ionizable cationic lipids
KR20250031230A (ko) 2022-05-25 2025-03-06 아카제라 메디신즈, 인크. 핵산 전달을 위한 지질 나노입자 및 이의 사용 방법

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0740701B1 (fr) 1994-01-13 2006-12-06 The Regents of the University of California Recepteurs de proteine chimioattractive monocytaire de mammifere
EP0883687B1 (fr) 1996-03-01 2004-10-27 Euroscreen S.A. Recepteur-5 de chimiokine cc, recepteur de chimiokines cc, leurs derives et leurs applications
AU3375697A (en) 1996-05-28 1998-01-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cc chemokine receptor 5, antibodies thereto, transgenic animals
US6388055B1 (en) 1996-10-03 2002-05-14 Smithkline Beecham Corporation Mouse CC-CKR5 receptor polypeptide
AR008331A1 (es) 1997-01-23 1999-12-29 Smithkline Beecham Corp Compuestos antagonistas de un receptor de il-8, uso de los mismos para la fabricacion de medicamentos, procedimiento para su obtencion, composicionesfarmaceuticas que los contienen
WO1999032100A2 (fr) * 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Composition pharmaceutique antagoniste de ccr5 et contenant un derive d'anilide
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
WO2000037455A1 (fr) 1998-12-21 2000-06-29 Takeda Chemical Industries, Ltd. Derives de benzothiepin-anilide, production et utilisation comme antagoniste de ccr-5
AU2000227285A1 (en) 2000-01-14 2001-07-24 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods of regulating il-12 production by administering ccr5 agonists and antagonists
RU2252786C2 (ru) 2000-09-08 2005-05-27 Микромет Аг Конструкции антител и хемокинов и их применение при иммунологических нарушениях
NZ532018A (en) 2001-10-03 2004-12-24 Ucb S Pyrrolidinone derivatives
US20060251651A1 (en) 2002-12-13 2006-11-09 Ono Pharmaceutical Co., Ltd. Antagonist and agonist which bind to a strong binding site of chemokine receptor
JPWO2004098638A1 (ja) 2003-05-06 2006-07-13 小野薬品工業株式会社 エフェクター細胞機能阻害剤
US7943130B2 (en) 2003-12-11 2011-05-17 Yale University Methods and compositions relating to CCR5 antagonist, IFN-γ and IL-13 induced inflammation
CN102344398B (zh) * 2003-12-18 2015-02-25 因赛特公司 作为趋化因子受体调控剂的3-环烷基氨基吡咯烷衍生物
GB0403038D0 (en) * 2004-02-11 2004-03-17 Novartis Ag Organic compounds
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
JP2007537264A (ja) * 2004-05-11 2007-12-20 インサイト コーポレイション ケモカインレセプタのモジュレータとしての３−（４−ヘテロアリールシクロヘキシルアミノ）シクロペンタンカルボキサミド
GB0412468D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
WO2007062175A2 (fr) 2005-11-21 2007-05-31 Amgen Inc. Antagonistes cxcr3
GB0525957D0 (en) 2005-12-21 2006-02-01 Astrazeneca Ab Methods
AU2007258907A1 (en) 2006-06-12 2007-12-21 Pfizer Products Inc. CCR5 antagonist for enhancing immune reconstitution and treating opportunistic infection in HIV patients
US20080076120A1 (en) 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
CA2665808A1 (fr) 2006-10-05 2008-05-22 Centocor Ortho Biotech Inc. Antagonistes de ccr2 pour le traitement de la fibrose
WO2008045564A2 (fr) 2006-10-12 2008-04-17 Epix Delaware, Inc. Composés de carboxamide et leur utilisation
US8754107B2 (en) 2006-11-17 2014-06-17 Abbvie Inc. Aminopyrrolidines as chemokine receptor antagonists
JP2010519216A (ja) 2007-02-15 2010-06-03 ファイザー・リミテッド Ｃｃｒ５拮抗薬のための医薬組成物および方法
WO2008134076A1 (fr) 2007-04-30 2008-11-06 Progenics Pharmaceuticals, Inc. Procédés de réduction de la charge virale chez des patients infectés par le vih-1

Also Published As

Publication number Publication date
NZ578663A (en) 2011-01-28
GT200900226A (es) 2010-07-02
WO2008101905A1 (fr) 2008-08-28
BRPI0807625A2 (pt) 2014-05-27
EA017000B1 (ru) 2012-09-28
ES2371126T3 (es) 2011-12-27
AR065369A1 (es) 2009-06-03
MX2009008145A (es) 2009-08-12
JP2010519187A (ja) 2010-06-03
CL2008000497A1 (es) 2008-08-29
ECSP099584A (es) 2009-09-29
RS51986B (sr) 2012-02-29
HRP20110793T1 (hr) 2011-11-30
ATE518854T1 (de) 2011-08-15
IL200191A0 (en) 2010-04-15
AU2008219317B2 (en) 2011-09-08
PT2125782E (pt) 2011-11-17
HN2009001607A (es) 2011-11-23
US8354431B2 (en) 2013-01-15
EP2125782A1 (fr) 2009-12-02
TW200848038A (en) 2008-12-16
KR20090103943A (ko) 2009-10-01
AU2008219317A1 (en) 2008-08-28
UA97389C2 (en) 2012-02-10
TN2009000345A1 (en) 2010-12-31
EA200901085A1 (ru) 2010-02-26
US20100016361A1 (en) 2010-01-21
ZA200905160B (en) 2010-05-26
KR101070984B1 (ko) 2011-10-06
CA2677565A1 (fr) 2008-08-28
HK1138836A1 (en) 2010-09-03
CN101605781A (zh) 2009-12-16
JP5180234B2 (ja) 2013-04-10
PE20081785A1 (es) 2009-01-12
PL2125782T3 (pl) 2011-12-30
CN101605781B (zh) 2014-08-13
MY147487A (en) 2012-12-14
EP2125782B1 (fr) 2011-08-03
SI2125782T1 (sl) 2011-12-30
CY1111984T1 (el) 2015-11-04
CR10957A (es) 2009-09-01
IL200191A (en) 2013-12-31
CA2677565C (fr) 2014-11-18
DK2125782T3 (da) 2011-11-21

Similar Documents

Publication Publication Date Title
BRPI0716598A2 (pt) Derivados de (hetero) arilsulfonamida de n-biarila úteis no tratamento de doenças medidas por interações de linfócitos
PL2229356T3 (pl) 1,2-Dipodstawione pochodne 4-benzyloamino-pirolidyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic
ATE506354T1 (de) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
EP1724262A4 (fr) Derive de 1-(2h)-isoquinolone
CR10499A (es) Profarmaco de compuesto de cinamida
TW200728307A (en) Novel spirochromanone derivatives
MA35452B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
HRP20120323T1 (en) Diarylhydantoin compounds
ATE404536T1 (de) Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
AR062211A1 (es) Derivados de 6-carboxi-normorfinano. composiciones farmaceuticas
MA32240B1 (fr) Inhibiteurs de désacétylases b à base d'hydroxamate
EA201100994A1 (ru) Способ получения производных бисфуранового спирта, соединения, соль, фармацевтическая композиция на ее основе, способ лечения или профилактики ретровирусных инфекций с ее помощью
MA33618B1 (fr) Agent thérapeutique destiné aux troubles de l'humeur
CY1111271T1 (el) Παραγωγο τριαζολονης
MA30341B1 (fr) Dérivés de benzimidazole
ATE492534T1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
EA201071424A1 (ru) Сульфонатные соли 2-амино-3-карбэтоксиамино-6-(4-фторбензиламино)пиридина
TW200637539A (en) CTGF inhibitors
MA31206B1 (fr) Dérivés cyclohexyl amide d'acide carboxylique aryle
EA200700997A1 (ru) 2,5- и 2,6-дизамещенные аналоги бензазола, полезные в качестве ингибиторов протеинкиназ
AR077429A1 (es) Compuestos hidroxiasenapina sus derivados y composiciones farmaceuticas que comprenden los mismos
ATE466007T1 (de) 5-substituierte indol-2-carbonsäureamidderivate
MY145122A (en) Phenylacetic acid derivatives as cox-2 inhibitors
EA200900480A1 (ru) Новые соединения индола, способ их получения и фармацевтические композиции, которые их содержат
EA200700322A1 (ru) Оксазолидиноны, содержащие оксиндолы, в качестве антибактериальных агентов